TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10051499
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of plasma-derived vaccine (group 3)
Study: 8635039
Drug: Metoclopramide (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (80 mg/m2 iv loading dose followed by 20 mg/m2/hr) with dronabinol 5 mg/m2
Study: 8635039
Drug: Prochlorperazine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine (6 mg/m2 intravenous loading dose followed by 1.5 mg/m2/hour) with dronabinol 5 mg/m2
Study: 8635039
Drug: Metoclopramide (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (80 mg/m2 iv loading dose followed by 20 mg/m2/hr) without dronabinol
Study: 8635039
Drug: Prochlorperazine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine (6 mg/m2 intravenous loading dose followed by 1.5 mg/m2/hour) without dronabinol
Study: 6783059
Drug: Exercise without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise without preliminary treatment
Study: 30640482
Drug: CBT +
Normalized name: Cannabidiol
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBT + MM (Cognitive Behavioral Therapy + Mindfulness Meditation)
Study: 30640482
Drug: CBT +
Normalized name: Cannabidiol
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBT + PMR (Cognitive Behavioral Therapy + Progressive Muscle Relaxation)
Study: 29157275
Drug: Combination community-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination community-based intervention (CBI)
Study: 26017304
Drug: Pasireotide 40
Normalized name: pasireotide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 40 mg every 28 days
Study: 26017304
Drug: Pasireotide 40
Normalized name: pasireotide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 40 or 60 mg every 28 days
Study: 22847485
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT), 8-session group format
Study: 16567606
Drug: Perindopril (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (8 mg/d)
Study: 7978427
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg R 80122
Study: 25851895
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) 5 μg/kg/q12h for 5 days
Study: 12584036
Drug: iv pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv pamidronate 120 mg for Group I, 180 mg for Group II, 240 mg for Group III
Study: 10874063
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants for six weeks
Study: 9086359
Drug: Riluzole (antiglutamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole (antiglutamate agent)
Study: 1577047
Drug: Adinazolam (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adinazolam (5, 10, 15, 20 mg)
Study: 1577047
Drug: NDMAD (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NDMAD (10, 20, 30, 40 mg)
Study: 2857036
Drug: Flupenthixol (depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupenthixol (depot injection)
Study: 26303968
Drug: Fluor Protector
Normalized name: Fluor a Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluor Protector Gel(™) (FPG)
Study: 22286957
Drug: Low-dose acute
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acute tryptophan depletion (LD-ATD) with no tryptophan (T−)
Study: 15979652
Drug: NTX plus
Normalized name: NTx-265
DrugBank: NTx-265 (DB05649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTX plus prazepam (one 10-mg tablet twice daily)
Study: 15979652
Drug: NTX alone
Normalized name: NTx-265
DrugBank: NTx-265 (DB05649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTX alone (one 50-mg tablet daily)
Study: 15979652
Drug: NTX plus
Normalized name: NTx-265
DrugBank: NTx-265 (DB05649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTX plus placebo (one 50-mg tablet daily plus one tablet twice daily)
Study: 15979652
Drug: No pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pharmacological treatment (control group)
Study: 11035992
Drug: Surgical treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatments (hysterectomy, abdominal myomectomy, laparoscopic myomectomy, myolysis)
Study: 11035992
Drug: Nonsurgical treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatments (uterine artery embolization, medical therapy)
Study: 8813271
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IvIg) 0.4 g per kg body weight
Study: 30221336
Drug: Cepodoxime (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cepodoxime (100 mg twice per day)
Study: 30221336
Drug: Cepodoxime (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cepodoxime (100 mg) and aceclofenac (100 mg twice per day)
Study: 18826865
Drug: Grape juice
Normalized name: grape juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape juice with diltiazem 180 mg
Study: 18826865
Drug: Orange juice
Normalized name: Orange juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange juice with diltiazem 180 mg
Study: 18826865
Drug: Water with
Normalized name: sterile water with electrolytes injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water with diltiazem 180 mg
Study: 12576870
Drug: 10 mg.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg. atrasentan
Study: 12576870
Drug: 2.5 mg.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg. atrasentan
Study: 8753111
Drug: 1800 micrograms/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800 micrograms/day of inhaled beclomethasone dipropionate (BDP) and bronchodilators
Study: 8753111
Drug: 1400 micrograms/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1400 micrograms/day of inhaled beclomethasone dipropionate (BDP) and bronchodilators
Study: 8753111
Drug: 1800 micrograms/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800 micrograms/day of inhaled beclomethasone dipropionate (BDP)
Study: 8753111
Drug: 1800 micrograms/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800 micrograms/day of inhaled beclomethasone dipropionate (BDP) and 1400 micrograms/day of BDP
Study: 29540424
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of 1000 IU fIX prothrombin complex concentrate (PCC)
Study: 29540424
Drug: Variable dose
Normalized name: methohexital
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Variable dose of prothrombin complex concentrate (PCC) determined by patient-specific bodyweight and international normalised ratio
Study: 24929888
Drug: Buccal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal misoprostol 400 mcg (1-2 doses, administered at least 3 hours before D&E)
Study: 24929888
Drug: Buccal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal misoprostol 400 mcg
Study: 15711571
Drug: BuCyVP (etoposide
Approvals — FDA: no, EMA: no, PMDA: no
Description: BuCyVP (etoposide 60 mg/kg, busulfan 14 mg/kg, cyclophosphamide 120 mg/kg)
Study: 9609264
Drug: Ampicillin 500
Normalized name: ampicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 500 mg intra-operatively
Study: 30769
Drug: Lorazepam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (3 mg per day, given b.i.d., 2 mg h.s. and 1 mg a.m. for 4 weeks)
Study: 19340512
Drug: NEM(R) 500
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEM(R) 500 mg daily for 8 weeks
Study: 12718461
Drug: Clinical guidelines
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical guidelines plus postal feedback on prescribing patterns for antibiotics
Study: 10930561
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light (5000 lux) and caffeine (100 mg)
Study: 9382473
Drug: Macrophage-targeted glucocerebrosidase
Normalized name: PEG-Glucocerebrosidase
DrugBank: PEG-Glucocerebrosidase (DB17660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macrophage-targeted glucocerebrosidase (Ceredase) infusions, dosage ranged from 120 to 480 U/kg of body weight/month
Study: 9382473
Drug: Macrophage-targeted glucocerebrosidase
Normalized name: PEG-Glucocerebrosidase
DrugBank: PEG-Glucocerebrosidase (DB17660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macrophage-targeted glucocerebrosidase (Ceredase) infusions
Study: 8266769
Drug: Octreotide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (100 micrograms tds) by subcutaneous injection for 12 days
Study: 8266769
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections for 12 days
Study: 3534901
Drug: Pyritinol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyritinol (200 mg, three times daily)
Study: 23026303
Drug: Placebo (controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (controlled medication)
Study: 16230523
Drug: Omapatrilat (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat (80 mg)
Study: 16230523
Drug: Enalapril (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (40 mg)
Study: 11850097
Drug: Hydroxychloroquine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (up to 300 mg bid)
Study: 6999827
Drug: Ketocaine compresses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketocaine compresses (10% ethanol solution)
Study: 12656658
Drug: Selenomethionine (Seme)
Normalized name: selenomethionine
DrugBank: Selenomethionine (DB11142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selenomethionine (Seme) 200 microg plus L-thyroxine (LT(4))
Study: 12656658
Drug: L-thyroxine (LT(4))
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine (LT(4)) plus placebo
Study: 11152061
Drug: Herbal dietary
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal dietary supplement containing 10 mg of caffeine and 5 mg of ephedrine
Study: 8446844
Drug: Ketotifen, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen, 2 mg twice daily for 7 days
Study: 8446844
Drug: Ketotifen, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen, 2 mg twice daily for 24 hours before indomethacin administration
Study: 3946946
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg doxepin
Study: 3946946
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg doxepin
Study: 27120106
Drug: Infant formula
Normalized name: Infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant formula with 0.3 g/dl GOS (OM55N)
Study: 21129229
Drug: UF-heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: UF-heparin
Study: 16395369
Drug: MOD inlay
Normalized name: MOD-423 hGH analogue
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: MOD inlay preparation (Group A)
Study: 14595300
Drug: Endoscopic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic therapy for Forrest Ib‐IIb ulcers with positive Doppler signal
Study: 14595300
Drug: Endoscopic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic therapy for Forrest IIc‐III ulcers with positive Doppler signal
Study: 14595300
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy for Forrest IIc‐III ulcers with positive Doppler signal
Study: 14595300
Drug: Doppler signal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doppler signal present after endoscopic therapy
Study: 8707096
Drug: 5 MU
Normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 MU injections (group A)
Study: 8707096
Drug: 1.5 MU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 MU injections (group B)
Study: 8707096
Drug: Increasing the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing the dose of interferon in group B
Study: 8707096
Drug: 1.5 MU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 MU injections (group B) with normal ALT
Study: 2735516
Drug: Oral 'booster'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 'booster' (n = 10)
Study: 21215382
Drug: Telehealth lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth lifestyle counseling (active control plus 6 weekly 1‐hour teleconferenced sessions to groups of 4 to 8 subjects)
Study: 16053970
Drug: Ambrisentan 1
Normalized name: ambrisentan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan 1 mg
Study: 16053970
Drug: Ambrisentan (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan (all doses combined)
Study: 9880769
Drug: Chemotherapy (5-fluorouracil-based)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (5-fluorouracil-based)
Study: 9880769
Drug: Chemotherapy (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (various drugs including gemcitabine)
Study: 7701406
Drug: Standard Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Heparin (UFH)
Study: 18661524
Drug: Yttrium-90-labeled murine
Normalized name: yttrium
DrugBank: Yttrium Y-90 (DB13076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yttrium-90-labeled murine HMFG1 plus standard treatment (AT)
Study: 10363736
Drug: Loracarbef (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loracarbef (15 mg/kg)
Study: 10363736
Drug: Clarithromycin (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (7.5 mg/kg)
Study: 7234386
Drug: Pooled human
Normalized name: Coagulation Factor X (Pooled Human Plasma)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled human milk feeding regimen, protein intake: 2.0 g/kg/day
Study: 7234386
Drug: Cow's milk
Normalized name: Cow's milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cow's milk based infant formula feeding regimen, protein intake: 4.4 g/kg/day
Study: 21299844
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER 6-12 mg/day
Study: 21299844
Drug: Risperidone 2-4
Normalized name: risperidone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 2-4 mg/day
Study: 20024739
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) use
Study: 1527157
Drug: Trimetazidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (20 mg, t.i.d. for 3 weeks before surgery and added to cardioplegic solutions at 10(-6) M)
Study: 21591384
Drug: 1 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/day omega-3 polyunsaturated fatty acids for 1 month
Study: 21591384
Drug: 1 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/day omega-3 polyunsaturated fatty acids continued for a second month
Study: 21591384
Drug: 1 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/day omega-3 polyunsaturated fatty acids stopped after one month
Study: 19419925
Drug: Paclitaxel and
Normalized name: paclitaxel and encequidar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel and docetaxel (standard therapies)
Study: 19419925
Drug: Novel taxanes
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel taxanes (single agents and in combination regimens)
Study: 11836041
Drug: ccHRT (conjugated
Approvals — FDA: no, EMA: no, PMDA: no
Description: ccHRT (conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg)
Study: 18800454
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg) and Captopril (50 mg)
Study: 29380563
Drug: CD34+ cell
Normalized name: CD34+ Cells
DrugBank: Autologous peripheral blood-derived CD34+ cells (DB16367)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD34+ cell therapy (Stem Cells Group, n=30)
Study: 29380563
Drug: No cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cell therapy (Controls, n=30)
Study: 26786756
Drug: Aluminium oxide
Normalized name: Aluminium oxide
DrugBank: Aluminum oxide (DB11342)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminium oxide (Al2O3) exposure (3.8-4.0 mg/m3) for 2 hours including 30 minutes of exercise
Study: 20854563
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of daily living (ADL) performance
Study: 17177576
Drug: Switching to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching to aripiprazole from maintenance therapy with another antipsychotic
Study: 7983603
Drug: 900-mg theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 900-mg theophylline doses as three 300-mg once-a-day theophylline capsules in the morning
Study: 7983603
Drug: 900-mg theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 900-mg theophylline doses as three 300-mg once-a-day theophylline capsules in the evening
Study: 7983603
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules administered midway between each dose of active drug
Study: 8218753
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg t.d.s.; total dose 750 mg)
Study: 353720
Drug: Nomifensine (50-225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomifensine (50-225 mg daily)
Study: 27753718
Drug: Self-reported risky
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported risky drug use
Study: 22901554
Drug: Lingonberry powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lingonberry powder with glucose (50 g)
Study: 22901554
Drug: Lingonberry powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lingonberry powder with triacylglycerols (35 g)
Study: 9825367
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg SDZ WAG994 orally
Study: 2562233
Drug: Magnesium valproate
Normalized name: magnesium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium valproate (MV) 1200 mg daily
Study: 2562233
Drug: Magnesium valproate
Normalized name: magnesium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium valproate (MV) 400 mg single dose
Study: 2562233
Drug: Long-term therapy
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term therapy with magnesium valproate (MV)
Study: 23701571
Drug: Fruit-juice drink
Normalized name: Morinda citrifolia fruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruit-juice drink (FJD) with 500 mL
Study: 22868522
Drug: Budesonide/formoterol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol combination (BUD/FM) 320/9 μg/day
Study: 22868522
Drug: Budesonide plus
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide plus tulobuterol patch (BUD + Tulo)
Study: 18391102
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of nicotine
Study: 1346170
Drug: Protocol group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol group (pHi-guided therapy)
Study: 3883737
Drug: Molsidomine 2
Normalized name: molsidomine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine 2 or 4 mg single oral dose
Study: 3883737
Drug: Molsidomine 8
Normalized name: molsidomine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine 8 to 24 mg/24 hours
Study: 31408030
Drug: Microbicide candidates
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microbicide candidates (various dosing mechanisms including vaginal gel, oral tablet, ring)
Study: 23206451
Drug: Atorvastatin (steady-state)
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (steady-state)
Study: 23206451
Drug: All drugs
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drugs (alone or in combination)
Study: 16048137
Drug: 25 hydroxyvitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 hydroxyvitamin D3 [25(OH)D], 50 microg twice a week for 14 days (Study 1)
Study: 16048137
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 800 IU (20 microg) daily for 12 months (Study 2)
Study: 11993510
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (sulfasalazine and azathioprine)
Study: 11993510
Drug: Sulfasalazine monotherapy
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfasalazine monotherapy (placebo)
Study: 8534781
Drug: Theophylline (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (loading dose 5 mg/kg i.v., maintenance dose 2.5 mg/kg/12 h)
Study: 8534781
Drug: Caffeine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (loading dose 10 mg/kg i.v., maintenance dose 2.5 mg/kg/12 h)
Study: 25973526
Drug: MNTX (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: MNTX (8 mg or 12 mg by body weight, administered every other day for two weeks)
Study: 25973526
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered every other day for two weeks)
Study: 24172161
Drug: Escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10 and 20 mg/day)
Study: 22859237
Drug: Alefacept 15
Normalized name: alefacept 15 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alefacept 15 mg intramuscularly once weekly for 12 weeks plus nbUVB three times weekly
Study: 22859237
Drug: Alefacept 15
Normalized name: alefacept 15 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alefacept 15 mg intramuscularly once weekly for 12 weeks
Study: 17594251
Drug: Preparation stage
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation stage at baseline
Study: 15226169
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medications
Study: 9822095
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (alpha-tocopherol acetate, 300 mg/day)